Trials / Terminated
TerminatedNCT02013778
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
Phase I-II Clinical Trial of the Safety and Preliminary Efficacy of Hydroxychloroquine Combined With Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC). A conventional 3+3 design will be utilized. Primary Phase II: To evaluate the complete response rate in a cohort of patients treated at the MTD, A Simon's Optimal Two-stage design will be utilized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCQ |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2018-11-01
- Completion
- 2019-02-01
- First posted
- 2013-12-17
- Last updated
- 2020-04-20
- Results posted
- 2020-04-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02013778. Inclusion in this directory is not an endorsement.